Document resource
Background and Importance Eptinezumab is a calcitonin gene-related peptide antagonist (anti-CRGP) funded by the national health system for the following indications: patients with ≥8 migraine days/month (MMD), high-frequency episodic migraine (HFEM) and in patients with chronic migraine (CM) and ≥3 failures of previous treatments used for at least 3 months, one of which was botulinum toxin in the case of CM.Aim and Objectives To evaluate the real-world efficacy and safety of eptinezumab in our hospital.Material and Methods An observational, descriptive, and retrospective study was conducted that included all patients with CM (≥15 MMD) or HFEM (10-15 MMD) who received at least one dose of eptinezumab at our hospital between April 24 and June 25.The following data were collected age, sex, migraine type, number of migraine-naïve patients, number of patients receiving botulinum toxin, MMD at baseline and week 12, prior treatments, and adverse reactions (ADR). The efficacy variables analysed were MMD reduction at week 12, the percentage of patients with ≥75% MMD reduction, and ≥50% MMD reduction.Data were analysed using measures of central tendency and dispersion for quantitative variables and absolute frequencies for qualitative variables. Differences between quantitative variables were analysed using the Wilcoxon test using IBM SPSS.Results Thirty-eight patients (89% women) with CM (95%) and HFEM (5%) were included, with a median age of 45 [range 17-80] years. Only 16% of patients were treatment-naïve, and the remaining 71% had previously received other anti-CRGP agents. All patients with CM had received botulinum toxin.The overall median at baseline was 20 MMD (95% CI: 13,53 to 26,47), and at week 12, a significant reduction to 11.5 MMD (95% CI: 4,52 to 18,48) was observed; p<0.0001. 2/38 patients had a ≥75% reduction in MMD, and 13/38 had a ≥50% reduction at week 12.7/38 patients experienced mild and transient ADR, the most notable being fatigue (9%).Conclusion and Relevance The reduction in MMD at week 12 of treatment is significant; however, further studies are needed to confirm the validity of the long-term results. Eptinezumab was well tolerated, with most reported adverse effects being mild.Conflict of Interest No conflict of interest